WuXi Biologics Included in FTSE4Good Index for Sixth Consecutive Year
WuXi Biologics (2269.HK) has been included in the FTSE4Good Index Series for the sixth consecutive year, recognizing its sustainability performance. The inclusion highlights the company's value creation through green CRDMO services.
WuXi Biologics (2269.HK), a global Contract Research, Development, and Manufacturing Organization (CRDMO), has once again been recognized for its sustainability performance. The company has been included in the FTSE4Good Index Series for the sixth year in a row.
This repeated inclusion in the FTSE4Good Index underscores WuXi Biologics' commitment to Environmental, Social, and Governance (ESG) principles. The index assesses companies based on their sustainability practices. WuXi Biologics' selection highlights its progress in creating green CRDMO services, aligning with its strategy for value creation.
Company executives stated that the recognition reflects a strong commitment to sustainability and long-term value creation. The organization has integrated ESG principles into its business strategy, aiming for responsible growth within the global biopharmaceutical industry.
WuXi Biologics has focused on enhancing its environmental efficiency and social impact. Efforts to reduce its ecological footprint and promote a safe working environment are key components of its operations. These initiatives support its position as a responsible player in the sector.
Inclusion in the FTSE4Good Index requires meeting stringent criteria, and continued success demonstrates WuXi Biologics' consistency in achieving its sustainability objectives.